WEBULL
WebtradeDownload

Cellebrite DI (CLBT) Following Guidance Cut And CEO Change, Is The Valuation Too Cheap To Ignore?

Simply Wall St · 1d ago

Cellebrite DI (NasdaqGS:CLBT) is back in focus after half year 2026 results, a planned CEO handover to Shiven Ramji, and a lower full year revenue outlook tied to its Inseyets expansion plans.

At a share price of US$11.29, Cellebrite DI has seen its 30 day share price return fall 20.58% and its year to date share price return fall 36.72%. However, the 3 year total shareholder return of 44.93% suggests longer term holders still sit on gains.

Compare Cellebrite DI's reset expectations with other software stocks by reviewing the hand picked 18 high quality undiscovered gems, which also pair digital growth stories with established fundamentals.

Bulls will point to Cellebrite DI's double digit revenue growth and long term shareholder gains. Bears will focus on the guidance cut and weaker earnings. Which side does the current valuation lean toward now?

Most Popular Narrative: 26.5% Undervalued

The most followed narrative currently pegs Cellebrite DI's fair value at $15.36, compared with the last close of $11.29, and builds its case around recurring, subscription driven growth.

The continued transition to a recurring, subscription-based revenue model, with over 90% of revenues now from subscriptions and growing SaaS/cloud penetration, improves revenue visibility, predictability, and operating leverage. This is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.

Read the complete narrative.

Want to see what underpins that $15.36 fair value for Cellebrite DI? The narrative leans heavily on revenue growth, rising margins, and a rich future earnings multiple. The exact mix of assumptions might surprise you.

Result: Fair Value of $15.36 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Cellebrite DI's heavy reliance on US federal contracts, along with rising competition in mobile security, could pressure growth and challenge the current undervaluation story.

Find out about the key risks to this Cellebrite DI narrative.

Another View: Cellebrite DI Looks Expensive On Earnings

The 26.5% undervaluation story for Cellebrite DI leans heavily on future cash flows and subscription growth. On current earnings though, the stock trades on a P/E of 48.6x, compared with 42.3x for peers and 30.8x for the wider US Software industry. The fair ratio sits even lower at 34.9x, which points to valuation risk if growth expectations slip. Which lens do you trust more today: the growth model or the current multiple?

For a closer look at how these earnings based signals stack up against expected growth, review the valuation breakdown and what the numbers imply for future expectations See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:CLBT P/E Ratio as at Aug 2026
NasdaqGS:CLBT P/E Ratio as at Aug 2026

Next Steps

With sentiment this mixed around Cellebrite DI, it makes sense to look at the full picture and move quickly to shape your own view. To weigh the trade off between the concerns and the potential upside, review the 4 key rewards and 2 important warning signs.

Looking for more ideas beyond Cellebrite DI?

If you stop at Cellebrite DI, you risk missing other opportunities that could better match your goals. Use the screeners to pressure test and broaden your shortlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.